Dinuclear Ru(II) Complexes Containing Tetrapyrido[3,2‐a : 2,3‐c : 3,2‐h : 2′′′,3′′′‐j]Phenazine Ligand for Biomedical Applications DOI Open Access
Rajesh Kushwaha, Samya Banerjee

ChemBioChem, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 12, 2024

Ruthenium complexes are among the most extensively studied and developed luminescent transition-metal for anticancer applications. Dinuclear Ru(II) have caught significant interest larger size, higher charge, variable complex shapes. In this concept, we explored past recent works on possible biological applications of versatile tetrapyrido[3,2-a : 2,3-c 3,2-h 2''',3'''-j]phenazine (tppz)-based dinuclear with a focus their use as quadruplex DNA probes, organelle imaging, phototherapeutic agents. This concept also points out that particular type can act multitargeting multifunctional agents -making an exciting research area in which array further will likely emerge.

Language: Английский

RuIII–Morpholine-Derived Thiosemicarbazone-Based Metallodrugs: Lysosome-Targeted Anticancer Agents DOI
Monalisa Mohanty, Sanchita Das,

Pratikshya Das Pattanayak

et al.

ACS Applied Bio Materials, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 13, 2025

The idea of coordinating biologically active ligand systems to metal centers exploit their synergistic effects has gained momentum. Therefore, in this report, three RuIII complexes 1–3 morpholine-derived thiosemicarbazone ligands have been prepared and characterized by spectroscopy HRMS along with the structure 2 through a single-crystal X-ray diffraction study. solution stability was tested using conventional techniques such as UV–vis HRMS. Further, anticancer activity HT-29 HeLa cancer cell lines. To gain insight into mechanism action, cytotoxicity, hydrophobicity, interaction DNA HSA were evaluated different methods absorption, fluorescence, circular dichroism studies. Along favorable biomolecule interaction, revealed potent selectivity toward cells, which is prerequisite for generation an drug. According viability results, 1 highest cytotoxicity among all group, against both respectively. Additionally, fluorescence-active ruthenium selectively target lysosomes, live-cell imaging. disrupt lysosome membrane potential generating excessive amount reactive oxygen species, results apoptotic mode death.

Language: Английский

Citations

0
Photoredox-Mediated Immunotherapy Utilizing Rhenium(I) Photocatalysts with Electron Donor–Acceptor–Donor Configuration DOI
Dan Li, Gehui Wen, Haobing Wang

et al.

Journal of Medicinal Chemistry, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 24, 2025

The hypoxic environment of solid tumors significantly diminishes the therapeutic efficacy oxygen-dependent photodynamic therapy. Developing efficient photosensitizers that operate via photoredox catalysis presents a promising strategy to overcome this challenge. Herein, we report rational design two rhenium(I) tricarbonyl complexes (Re-TPO and Re-TP) with electron donor–acceptor–donor configuration. Notably, Re-TP exhibits aggregation-induced emission properties enhanced spin–orbit coupling compared Re-TPO, thus exhibiting promoted photosensitizing capability. In addition generating type I II reactive oxygen species, excited facilitates photocatalytic oxidation NADH NAD+ photoreduction pyruvic acid lactic acid. This metabolic intervention triggers PD-L1-linked immune responses disrupts tumor redox balance, leading ferroptosis immunogenic cell death. combined immunotherapy effects suppress both primary distant B16 tumors. investigation provides compelling model for designing metal-based PSs photoredox-mediated photoimmunotherapy against

Language: Английский

Citations

0
Intracellular Photocatalytic NADH/NAD(P)H Oxidation for Cancer Drug Development DOI
Ashish Yadav, Samya Banerjee,

Arif Ali Mandal

et al.

Journal of the American Chemical Society, Journal Year: 2025, Volume and Issue: 147(9), P. 7161 - 7181

Published: Feb. 20, 2025

Photocatalytic cancer therapy (PCT) has emerged as a cutting-edge anticancer mechanism of action, harnessing light energy to mediate the catalytic oxidation intracellular substrates. PCT is significant current importance due its potential address limitations conventional chemotherapy, particularly drug resistance and side effects. This approach offers noninvasive, targeted treatment option by utilizing metal-based photocatalysts induce redox metabolic disorders within cells. The disrupt cell metabolism converting NADH/NAD(P)H NAD+/NAD(P)+ via photoredox processes, altering NAD+/NADH or NAD(P)+/NAD(P)H ratios, which are crucial for cellular metabolism. Ir(III), Ru(II), Re(I), Os(II) demonstrated promising efficacy. Despite these developments, gaps remain in literature translating this new into clinical trials. Perspective critically examines developments research area provides future directions designing efficient PCT.

Language: Английский

Citations

0
Exploring photophysical, photochemical, and photobiological dynamics of binuclear transition metal complexes DOI

Rintu Bhowmik,

Abhishek Panwar,

Gobinda Bag

et al.

Coordination Chemistry Reviews, Journal Year: 2025, Volume and Issue: 537, P. 216689 - 216689

Published: April 13, 2025

Language: Английский

Citations

0
BODIPY-Based Photosensitizer with Outstanding Photocytotoxicity for Deep-Tissue Photodynamic Therapy DOI

Bin‐Kai Liu,

Kun‐Xu Teng, Li‐Ya Niu

et al.

ACS Materials Letters, Journal Year: 2025, Volume and Issue: unknown, P. 1947 - 1955

Published: April 19, 2025

Language: Английский

Citations

0
Recent advances in Rh(III)-based anticancer complexes DOI
Souvik Saha, Rajesh Kushwaha,

Apurba Mandal

et al.

Coordination Chemistry Reviews, Journal Year: 2024, Volume and Issue: 525, P. 216306 - 216306

Published: Nov. 22, 2024

Language: Английский

Citations

2
Facile fac- to mer-configuration transformation in tricyano Ru(II) complexes: Synthesis, luminescence, and potential application as chemical tracers for water flooding DOI
Shengzhen Hou, Jian Zhang,

Yue-Jun Zhu

et al.

Inorganic Chemistry Communications, Journal Year: 2024, Volume and Issue: unknown, P. 113257 - 113257

Published: Sept. 1, 2024

Language: Английский

Citations

0
New palladium complexes based on myrtenal and benzylamine derivatives: Selectivity of cyclometalation, antitumor activity DOI
O. A. Zalevskaya, Ya. A. Gur’eva,

A. V. Kutchin

et al.

Inorganica Chimica Acta, Journal Year: 2024, Volume and Issue: unknown, P. 122457 - 122457

Published: Nov. 1, 2024

Language: Английский

Citations

0
A Novel Substituted Benzo[g]quinoxaline-Based Cyclometalated Ru(II) Complex as a Biocompatible Membrane-Targeted PDT Colon Cancer Stem Cell Agent DOI Creative Commons
Alicia Marco, Jana Kašpárková,

Delia Bautista

et al.

Journal of Medicinal Chemistry, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 2, 2024

Herein, we describe and investigate biological activity of three octahedral ruthenium(II) complexes the type [Ru(C∧N)(phen)2]+, RuL1–RuL3, containing a π-expansive cyclometalating substituted benzo[g]quinoxaline ligand (C∧N ligand) (phen = 1,10-phenanthroline). Compounds RuL1–RuL3 in cervical, melanoma, colon human cancer cells exhibit high phototoxicity after irradiation with light (particularly blue), index reaching 100 for complex RuL2 most sensitive HCT116 cells. accumulates cellular membranes. If irradiated, it induces lipid peroxidation, likely connected photoinduced ROS generation. Oxidative damage to fatty acids leads attenuation membranes, activation caspase 3, triggering apoptotic pathway, thus implementing membrane-localized photodynamic therapy. is first photoactive ruthenium-based capable killing hardly treatable stem cells, highly resilient subpopulation within heterogeneous tumor mass, responsible recurrence metastatic progression cancer.

Language: Английский

Citations

0
Dinuclear Ru(II) Complexes Containing Tetrapyrido[3,2‐a : 2,3‐c : 3,2‐h : 2′′′,3′′′‐j]Phenazine Ligand for Biomedical Applications DOI Open Access
Rajesh Kushwaha, Samya Banerjee

ChemBioChem, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 12, 2024

Ruthenium complexes are among the most extensively studied and developed luminescent transition-metal for anticancer applications. Dinuclear Ru(II) have caught significant interest larger size, higher charge, variable complex shapes. In this concept, we explored past recent works on possible biological applications of versatile tetrapyrido[3,2-a : 2,3-c 3,2-h 2''',3'''-j]phenazine (tppz)-based dinuclear with a focus their use as quadruplex DNA probes, organelle imaging, phototherapeutic agents. This concept also points out that particular type can act multitargeting multifunctional agents -making an exciting research area in which array further will likely emerge.

Language: Английский

Citations

0